News
Homepage
/
2016

News Classification

Check category

News Center

Viwit Pharmaceuticals' Vildagliptin API Receives Official Approval by China NMPA 2023-12-07 08:31:28
On November 30, 2023, Viwit Pharmaceuticals received the "Notice of Approval of Application for Listing of Chemical APIs" issued by National Medical Products Administration (NMPA) for its independently developed active pharmaceutical ingredient (API), Vildagliptin. The registration number is Y20210000619, and the notice number is 2023YS00803.
Viwit Pharmaceuticals' Aprepitant API Receives Official Approval by China NMPA 2023-10-31 15:33:57
On October 26, 2023, Viwit Pharmaceuticals received the "Notice of Approval of Application for Listing of Chemical APIs" issued by China National Medical Products Administration (NMPA) for the independently developed active pharmaceutical ingredient (API) Aprepitant. The registration number is Y20210000473, and the notice number is 2023YS00727.
Viwit Pharmaceuticals obtained the Drug Production License C 2023-10-30 08:57:46
Congratulations to Viwit Pharmaceuticals that Viwit obtained the Drug Production License C for solid preparations and injections on July 28th, 2023. Meaning, that Viwit’s production lines for solid preparations and injections own the qualification on contracted manufacturing.
Viwit Pharmaceuticals’BFS Technology 2023-10-18 09:44:05
Viwit’s sterile blow-fill-seal (BFS) eye drops manufacturing facility is established in 2021. The BFS production line fulfills the need for an advanced aseptic manufacturing process using the state of the art Rommelag 434 BFS system. Pharmaceutical grade low-density polyethylene (PE) is used to ensure product quality and prevent leachable and leakage. A strip of 15 doses attached to each other can be created and filled within a few seconds. Every single BFS ampule is detected for leakage to ensure the integrity of the dose.
Meeting Viwit Pharmaceuticals at CPHI Barcelona 2023-09-18 14:48:00
Viwit Pharmaceuticals will be participating in CPHI Barcelona 2023 in Oct. 24th~26th, 2023 at Fira Barcelona Gran Via, Spain. Welcome to visit our booth 7D30 or contact us to learn more about our full portfolio of products, services, and solutions. We look forward to seeing you soon!
SST Corporation and Viwit Pharmaceuticals Establish Strategic Collaboration 2023-08-11 11:23:17
Having become an officially qualified API/CMC supplier to SST Corporation, Viwit and SST have established a strategic collaboration aiming to promote small molecule pharmaceutical contract development and manufacturing organization (CDMO) services in North America.

In 2016

12-07

Viwit Pharmaceuticals' Vildagliptin API Receives Official Approval by China NMPA

On November 30, 2023, Viwit Pharmaceuticals received the "Notice of Approval of Application for Listing of Chemical APIs" issued by National Medical Products Administration (NMPA) for its independently developed active pharmaceutical ingredient (API), Vildagliptin. The registration number is Y20210000619, and the notice number is 2023YS00803.
Viwit Pharmaceuticals' Vildagliptin API Receives Official Approval by China NMPA
10-31

Viwit Pharmaceuticals' Aprepitant API Receives Official Approval by China NMPA

On October 26, 2023, Viwit Pharmaceuticals received the "Notice of Approval of Application for Listing of Chemical APIs" issued by China National Medical Products Administration (NMPA) for the independently developed active pharmaceutical ingredient (API) Aprepitant. The registration number is Y20210000473, and the notice number is 2023YS00727.
Viwit Pharmaceuticals' Aprepitant API Receives Official Approval by China NMPA
10-30

Viwit Pharmaceuticals obtained the Drug Production License C

Congratulations to Viwit Pharmaceuticals that Viwit obtained the Drug Production License C for solid preparations and injections on July 28th, 2023. Meaning, that Viwit’s production lines for solid preparations and injections own the qualification on contracted manufacturing.
Viwit Pharmaceuticals obtained the Drug Production License C
10-18

Viwit Pharmaceuticals’BFS Technology

Viwit’s sterile blow-fill-seal (BFS) eye drops manufacturing facility is established in 2021. The BFS production line fulfills the need for an advanced aseptic manufacturing process using the state of the art Rommelag 434 BFS system. Pharmaceutical grade low-density polyethylene (PE) is used to ensure product quality and prevent leachable and leakage. A strip of 15 doses attached to each other can be created and filled within a few seconds. Every single BFS ampule is detected for leakage to ensure the integrity of the dose.
Viwit Pharmaceuticals’BFS Technology
09-18

Meeting Viwit Pharmaceuticals at CPHI Barcelona

Viwit Pharmaceuticals will be participating in CPHI Barcelona 2023 in Oct. 24th~26th, 2023 at Fira Barcelona Gran Via, Spain. Welcome to visit our booth 7D30 or contact us to learn more about our full portfolio of products, services, and solutions. We look forward to seeing you soon!
Meeting Viwit Pharmaceuticals at CPHI Barcelona
08-11

SST Corporation and Viwit Pharmaceuticals Establish Strategic Collaboration

Having become an officially qualified API/CMC supplier to SST Corporation, Viwit and SST have established a strategic collaboration aiming to promote small molecule pharmaceutical contract development and manufacturing organization (CDMO) services in North America.
SST Corporation and Viwit Pharmaceuticals Establish Strategic Collaboration
03-01

Viwit Pharmaceutical Invites You to Meet at CPHI North America

Viwit Pharmaceuticals will be participating in the CPHI North America conference this year from April 25- 27，2023 at Pennsylvania Convention Center, in Philadelphia. Welcome to stop by our booth # 1114 and explore how our CDMO services and solutions would benefit your drug development and manufacturing pipeline. We are looking forward to meeting and collaborating with you in the heart of the US pharma Industry!
Viwit Pharmaceutical Invites You to Meet at CPHI North America
Previous page
1
2
3
4
search
Confirm
Close
About Us
Company Introduction Corporate History Business Introduction Corporate Governance Company Culture Corporate Honors Viwit Family Media Center Video
R&D and Innovation
R&D Innovation Product Pipeline Achievements
Products
Drug Products Biologics APIs Intermediates Boranes
Innovation
CDMO Project Collaboration In-/Out-Licensing Joint Venture
Sustainable
EHS Energy Quality Supplier
News Center
In 2023 In 2022 In 2021 In 2020 In 2019 In 2018 In 2017 In 2016
Join Us
Talent Philosophy Talent Development Salary and Benefits Campus Recruiting Social Recruitment
Contact Us
Online Message Contact Us
dp EN
dp 中文

wz

wz